A detailed history of Raymond James Financial Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 166,611 shares of RNA stock, worth $11.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
166,611
Previous 151,235 10.17%
Holding current value
$11.8 Million
Previous $4.3 Million 69.01%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$28.46 - $50.36 $437,600 - $774,335
15,376 Added 10.17%
166,611 $7.26 Million
Q2 2025

Aug 14, 2025

SELL
$24.08 - $36.24 $193,338 - $290,970
-8,029 Reduced 5.04%
151,235 $4.3 Million
Q1 2025

May 13, 2025

SELL
$27.05 - $35.11 $1.07 Million - $1.39 Million
-39,643 Reduced 19.93%
159,264 $4.7 Million
Q4 2024

Feb 06, 2025

BUY
$29.08 - $52.5 $5.78 Million - $10.4 Million
198,907 New
198,907 $5.78 Million

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $3.69B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Raymond James Financial Inc Portfolio

Follow Raymond James Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Inc with notifications on news.